Our Pricing

Mounjaro vs Wegovy: Clinical Comparison for UK Patients

Choosing between mounjaro vs wegovy uk comparison options requires understanding how each medication works and what clinical trials reveal about their effectiveness. Both are MHRA-licensed injectable treatments that have transformed weight management outcomes, but they differ in mechanism, efficacy data, and side effect profiles. At Cured Pharmacy, our UK-registered clinical team helps you determine which treatment aligns with your health goals through a comprehensive online assessment.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK for weight management [1]. This dual-action mechanism activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, which regulate appetite, food intake, and glucose metabolism. The dual pathway approach represents a significant advancement over single-receptor medications.

Wegovy contains semaglutide, a selective GLP-1 receptor agonist that mimics the natural hormone GLP-1 [2]. It slows gastric emptying, reduces appetite, and enhances feelings of fullness after meals. While semaglutide has demonstrated substantial weight loss in clinical trials, its single-pathway mechanism differs fundamentally from tirzepatide's dual approach.

Both medications are administered as once-weekly subcutaneous injections using pre-filled pens. The dosing schedules differ: Mounjaro typically starts at 2.5mg and may be titrated up to 15mg, whilst Wegovy begins at 0.25mg and escalates to a maintenance dose of 2.4mg over several months. Your UK prescriber will determine the appropriate starting dose based on your medical history and weight loss objectives.

Mounjaro vs Wegovy Weight Loss Results: What Clinical Trials Show

The SURMOUNT-1 trial evaluated tirzepatide in adults with obesity or overweight, revealing that participants on the 15mg dose achieved an average weight reduction of 22.5% over 72 weeks [1]. This represents one of the highest efficacy rates observed in any weight management medication trial to date. Participants on lower doses of 10mg and 5mg achieved average reductions of 21.1% and 15.0% respectively.

By comparison, the STEP trials assessed semaglutide 2.4mg (Wegovy) in similar patient populations. The STEP 1 trial demonstrated an average weight loss of 14.9% over 68 weeks in adults without diabetes [2]. Whilst this represents clinically significant weight reduction, the head-to-head data suggests tirzepatide may produce greater average weight loss outcomes in comparable populations.

It's important to note that individual results vary considerably based on adherence to lifestyle modifications, baseline metabolic health, and genetic factors. Both medications require commitment to dietary changes and increased physical activity to achieve optimal outcomes. Your response to treatment will be unique, and your UK prescriber will monitor your progress through regular follow-up consultations.

Time to Results

Most patients begin noticing appetite reduction within the first two weeks of starting either medication, though measurable weight loss typically becomes apparent after 4-8 weeks [1][2]. Maximum weight loss effects are generally observed between 60-72 weeks of continuous treatment. Both medications require gradual dose escalation to minimise gastrointestinal side effects, which means optimal dosing may not be reached until several months into treatment.

Side Effects: Mounjaro vs Wegovy Comparison

Both tirzepatide and semaglutide share similar gastrointestinal side effect profiles, as both influence gut hormone pathways. The most commonly reported adverse effects include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort [1][2]. These symptoms are typically mild to moderate in severity and often diminish as your body adapts to the medication over several weeks.

Clinical trial data suggests that nausea occurs in approximately 30-40% of patients on Mounjaro and 20-30% on Wegovy, though most cases resolve within the first month [1][2]. Starting at the lowest dose and following the prescribed titration schedule significantly reduces the likelihood of severe gastrointestinal symptoms. Taking the injection on the same day each week and maintaining adequate hydration can also help manage these effects.

Rare but serious side effects include pancreatitis, gallbladder problems, and thyroid C-cell tumours (observed in rodent studies). Both medications carry a boxed warning regarding thyroid C-cell tumours and should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1][2]. Your UK prescriber will screen for these contraindications during your clinical assessment.

Managing Side Effects

If you experience persistent nausea or vomiting, eating smaller, more frequent meals and avoiding high-fat foods can help. Ginger tea and staying upright after meals may also provide relief. Contact your prescriber if side effects become severe or don't improve after the first few weeks, as dose adjustment may be necessary.

Cost Comparison: Mounjaro and Wegovy Pricing at Cured Pharmacy

Mounjaro is available at Cured Pharmacy from £135.00 per pen, with final pricing determined by your prescribed dose following clinical assessment. We maintain transparent upfront pricing, so you'll see exact costs before completing your consultation. Our pricing represents competitive UK market rates whilst ensuring you receive genuine MHRA-licensed medication dispensed by our GPhC-registered pharmacy.

Wegovy pricing starts from a lower entry point, making it an accessible option for many patients. The comparison table below shows starting prices across our weight loss injection range. Remember that the most cost-effective treatment isn't necessarily the cheapest per pen—it's the one that delivers optimal results for your individual circumstances with manageable side effects.

Both medications require ongoing treatment to maintain weight loss, so consider long-term costs when making your decision. Your UK prescriber will discuss treatment duration expectations during your consultation. At Cured Pharmacy, we offer lowest price guarantees across our range, and our superintendent pharmacist Tarun Kumar (GPhC 2233073) personally oversees quality assurance for every dispensed prescription.

Who Should Choose Mounjaro vs Wegovy?

Mounjaro may be particularly suitable for patients who require maximum weight loss efficacy or who have not achieved adequate results with single-pathway GLP-1 medications. The dual-receptor mechanism offers a distinct pharmacological advantage, and clinical data suggests higher average weight reduction compared to semaglutide [1][2]. However, it requires careful dose titration and medical supervision throughout treatment.

Wegovy remains an excellent choice for many patients, particularly those seeking a well-established treatment with extensive real-world safety data. It's been available longer than tirzepatide, meaning healthcare providers have more clinical experience managing patients on semaglutide. Some patients also find the side effect profile slightly more tolerable during the initial weeks of treatment.

Your suitability for either medication depends on multiple factors including your BMI, presence of weight-related comorbidities (such as type 2 diabetes, hypertension, or sleep apnoea), previous weight loss attempts, contraindications, and personal preferences. Both treatments are contraindicated in pregnancy, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation.

Clinical Assessment Process

At Cured Pharmacy, every prescription requires completion of a comprehensive online clinical assessment reviewed by a UK-registered prescriber. The assessment takes under three minutes and covers your medical history, current medications, allergies, and weight loss goals. Our clinical team will determine which treatment is most appropriate for your circumstances, or whether alternative options should be considered. You'll receive a clear treatment recommendation with dosing instructions and ongoing monitoring requirements.

Starting Your Weight Loss Treatment at Cured Pharmacy

Beginning treatment is straightforward: complete your free online consultation, receive prescriber approval, and your medication will be dispensed from our GPhC-registered pharmacy (registration number 9012511) with discreet next-day delivery available across the UK. We supply only genuine UK-licensed medications—every Mounjaro and Wegovy pen is sourced through legitimate pharmaceutical supply chains and stored according to MHRA temperature requirements.

Your treatment includes ongoing clinical support from our UK-registered pharmacy team. We recommend follow-up consultations every 4-12 weeks to monitor your progress, adjust dosing if needed, and address any concerns. Weight loss medications work best when combined with lifestyle modifications including a reduced-calorie diet and increased physical activity. Our team can provide guidance on evidence-based dietary approaches that complement your medication.

Both Mounjaro and Wegovy represent significant advances in weight management pharmacotherapy, offering clinically meaningful weight reduction for patients who meet prescribing criteria. Whether you choose tirzepatide or semaglutide, you're accessing treatments backed by robust clinical trial evidence and MHRA regulatory approval. Start your assessment today to discover which option our UK prescribers recommend for your individual needs.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4
5. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://products.mhra.gov.uk/

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to lifestyle modifications alongside medication. Mounjaro and Wegovy are prescription-only medicines and may not be suitable for everyone.